Showing 1 - 10 of 31
Regulatory compliance in unprecedented times: how to adapt but stay on track - a guide for the European life sciences industry
The COVID-19 pandemic has had an unprecedented impact on stakeholders in the UK and EU’s life sciences industry - from companies, to third parties, governments, regulators and insurers.
On 26 February 2021, the Home Office launched a consultation into how the Government might use legislation to improve protective security and organisational preparedness at publicly accessible locations across the UK. The consultation seeks views from anyone who might be affected by a new “Protect Duty”, from individuals to businesses and public authorities. The consultation closes on 2 July 2021.
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?
For some time, the regulatory framework applicable to cannabis products in Europe has been widely recognised as being particularly complex. As a result of this, companies frequently struggle with successfully navigating the regulatory regimes applicable in each country in which they sell. This looks set to continue as new UK requirements come into force on 1 April 2021.
2020 was a challenging year globally. However, the start of 2021 has welcomed the rapid roll out of the breakthrough COVID-19 vaccines in the UK, a ray of hope for a way out of the pandemic. Over 20 million people in the UK have already been given vaccine doses, with the hope that the majority of the UK adult population will be vaccinated by the end of 2021.
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare.
Our research identified five key risk themes that have implications and represent both challenges and opportunities for businesses, insurers, and wider society. This will assist in moving the conversation forward as we look beyond COVID-19, highlighting the important need to reshape the dynamic relationship between companies, households, and insurers.
From the Insurance Post Claims and Fraud summit 2020, in this video James Shrimpton, Partner at Kennedys, focuses on the legal basis for Covid-19 infection claims, current medical research, the impact of the pandemic on other injury claims and whether we will see a flood of infection claims.
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?